The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis

Intensive Care Med. 2022 Jun;48(6):768-769. doi: 10.1007/s00134-022-06679-0. Epub 2022 Mar 17.

Matthias Gijsen^{1

2}, Erwin Dreesen³, Joost Wauters^{4

5}, Yves Debaveye^{6

7}, Isabel Spriet^{3

8}

¹ Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. matthias.gijsen@uzleuven.be.
² Pharmacy Department, University Hospitals Leuven, Leuven, Belgium. matthias.gijsen@uzleuven.be.
³ Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
⁴ Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.
⁵ Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Leuven, Belgium.
⁶ Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.
⁷ Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
⁸ Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

No abstract available

Publication types